Deals & Corporate Governance

  • January 27, 2026

    Biotech Fundraising A Good Sign For Public Markets

    At the start of what many healthcare attorneys hope will be a busy year, public biotechs are raising cash, signaling a thawing public market and potentially fertile ground for IPOs.

  • January 26, 2026

    Healthcare Group Of The Year: Holland & Knight

    Holland & Knight LLP attorneys advised AdventHealth on its multimillion-dollar outpatient acquisitions, Evernorth Health Services' $3.5 billion investment in Shields Health Solutions and Palomar Health on its strategic partnership with the University of California San Diego, earning it a spot among the 2025 Law360 Healthcare Groups of the Year.

  • January 23, 2026

    DC Circ. Revives Terrorism Liability Suit Against Pharma Cos.

    A D.C. Circuit panel revived a lawsuit Friday accusing pharmaceutical companies of aiding a Hezbollah-linked militia's terrorism in Iraq, saying the victims behind the case have adequately alleged that the companies' participation was conscious and voluntary. 

  • January 23, 2026

    Heart Valve Deal Was Blocked Over Innovation Concerns

    The D.C. federal court ruling earlier this month that upended a deal for Edwards Lifesciences Corp. to purchase JenaValve Technology Inc. was based on concerns that the deal would reduce innovation by eliminating competition for a heart valve treatment that's still being developed, according to a ruling unsealed on Friday by the judge who issued it.

  • January 21, 2026

    Health Tech SPAC Execs Ink $10M Investor Settlement

    Former executives of a health technology company that went public via merger with a blank check company have reached a $10 million deal to settle claims they wiped out investors with a bankruptcy filing after the company's product development projections derailed.

  • January 20, 2026

    Justices To Clarify What's Fair Game With 'Skinny Labels'

    A new U.S. Supreme Court patent case that will require the justices to spell out what generic-drug makers can say when marketing drugs with so-called skinny labels will shape whether and how those companies use the tactic of carving out patented uses from labels, attorneys say.

  • January 20, 2026

    What JPM Tells Us About Healthcare Deals In 2026

    Coming out of one of the bellwether events for the healthcare industry, attorneys in the space are feeling pretty good about 2026.

  • January 20, 2026

    Law360 Names Firms Of The Year

    Eight law firms have earned spots as Law360's Firms of the Year, with 48 Practice Group of the Year awards among them, achieving milestones such as high-profile litigation wins at the U.S. Supreme Court and 11-figure merger deals.

  • January 20, 2026

    CorMedix Investors Seek First OK Of Governance Reform Deal

    Investors in CorMedix Inc. have told a New Jersey federal judge that company directors have agreed to implement several corporate governance reforms to resolve a consolidated shareholder derivative lawsuit accusing the executives of making misleading statements about delays in the regulatory approval of the company's lead drug candidate.

  • January 16, 2026

    Law360 Names Practice Groups Of The Year

    Law360 would like to congratulate the winners of its Practice Groups of the Year awards for 2025, which honor the attorney teams behind litigation wins and significant transaction work that resonated throughout the legal industry this past year.

  • January 16, 2026

    Lifecore Investors Ink $3.8M Deal In Accounting Controls Suit

    Biotech company Lifecore Biomedical Inc. has reached a $3.8 million deal with its investors to end their claims the company had weak controls over its financial reporting, impairing its ability to remain compliant with Nasdaq listing requirements and causing share declines.

  • January 16, 2026

    Bioness $110M Sale Suit Heads to $8.9M Deal

    A Delaware Chancery Court class action challenging the $110 million sale of medical device maker Bioness Inc. to Bioventus Inc. is reaching a resolution through an $8.9 million proposed settlement, capping years of litigation over whether the deal was engineered to favor the company's controlling creditor at the expense of minority stockholders.

  • January 15, 2026

    Ex-CEO Of COVID Vax Maker Accused Of Insider Trading

    New York Attorney General Letitia James on Thursday sued the former CEO of healthcare contractor Emergent BioSolutions Inc., alleging insider trading amid troubles manufacturing a COVID-19 vaccine, while signing a $900,000 settlement with the company over its approval of an executive trading plan.

  • January 14, 2026

    Biotech Co. CytoDyn In Talks To End Investor Class Action

    A federal judge has given the green light for biotech company CytoDyn Inc. and its former leadership to move forward with a potential settlement of a proposed class action that accused the company of misleading shareholders over the alleged approval of its COVID-19 and HIV drug.

  • January 13, 2026

    Dispatch From JPM: Fewer Health Deals Don't Dampen Mood

    Despite an unusual dearth of big deal announcements, attorneys at the annual J.P. Morgan healthcare conference in San Francisco are still feeling positive about 2026.

  • January 13, 2026

    Emails Show Deceit In Medicare Advantage Deal, NC Court Told

    Internal documents from Atrium Health Inc. show the company never intended to follow through on a partnership for a new Medicare Advantage health plan with a plan provider who spent tens of millions of dollars to get it off the ground, the providers' counsel told a North Carolina Business Court judge Tuesday.

  • January 12, 2026

    Prospect Medical Says Calif. Hospital Buyer Owes $11.6M

    Prospect Medical Holdings Inc. has asked a Texas bankruptcy judge to order the buyer of its California hospitals to cough up $11.6 million owed under an asset purchase agreement inked last year, saying it's at risk of administrative insolvency. 

  • January 12, 2026

    Sidley-Led Smith & Nephew Inks $450M Orthopaedics Deal

    Sidley Austin-advised Smith & Nephew said Monday it will acquire Gunderson Dettmer-led U.S. sports medicine company Integrity Orthopaedics and its Tendon Seam rotator cuff repair technology in a deal valued at up to $450 million.

  • January 09, 2026

    Ex-Doximity Exec Cops To $2.5M Insider Trading Scheme

    The former chief revenue officer of publicly traded medical professional networking platform Doximity pled guilty Friday in New York federal court to securities fraud in connection to allegations that he illegally profited more than $2.5 million by trading on private information about the company's finances and layoff plans.

  • January 09, 2026

    Biopharma Co. Secures D&O Coverage For Shareholder Suit

    A biopharmaceutical company is entitled to coverage for a suit alleging its board breached fiduciary duties under a pair of primary and excess directors and officers policies, a Delaware state court ruled, saying the suit is "meaningfully linked" to a previously noticed demand for books and records.

  • January 09, 2026

    Judge Blocks Edwards' $945M Heart Valve Deal

    A D.C. federal judge issued an order on Friday preventing Edwards Lifesciences Corp. from moving ahead with its planned $945 million deal for JenaValve Technology Inc., torpedoing the merger challenged by the Federal Trade Commission.

  • January 09, 2026

    NC Biz Court Bulletin: Trade Secrets Row, A Patient Data Deal

    The North Carolina Business Court closed out the year by tossing a trade secrets fight brought by a corrugated packing manufacturer against its onetime star salesman and signing off on a $2.45 million settlement ending claims a healthcare system sold patients' data to Meta.

  • January 08, 2026

    Ardent Health Investors Sue Over Revenue Accounting Issues

    Tennessee-based healthcare provider Ardent Health Inc. was hit with a proposed shareholder class action accusing it of misleading investors about the collectability of accounts receivable and the sufficiency of the company's malpractice liability insurance, saying shares fell over 30% several weeks ago after the company reported disappointing earnings due to those issues.

  • January 08, 2026

    FTC Battles Edwards On Eve Of Heart Valve Merger Deadline

    The Federal Trade Commission asked a D.C. federal judge for a last-minute extension on an order blocking Edwards Lifesciences' $945 million acquisition of JenaValve Technology Inc., fearing difficulty with unscrambling the egg if the block expires Friday, the judge rejects its merger challenge and the deal closes before the agency can appeal.

  • January 08, 2026

    Dentists Look To Fill Holes After Delta Dental Class Cert. Denial

    Dentists targeting an alleged $13 billion antitrust scheme by Delta Dental and its members are asking an Illinois federal court for permission to amend their complaint after the court refused to grant their bid for class certification last year.

Expert Analysis

  • How Biotech Deals May Help Competition, Despite FTC View

    Author Photo

    The Federal Trade Commission's complaint against Sanofi's proposed partnership with Maze Therapeutics highlights increasing skepticism of so-called killer acquisitions, but a closer look reveals potentially legitimate reasons behind why entities might decide to delay or abandon the development of acquired products, say consultants at Analysis Group.

  • Notes Of Interest From 5th Circ. Illumina-Grail Merger Ruling

    Author Photo

    Attorneys at Simpson Thacher consider the Fifth Circuit's recent decision upholding the Federal Trade Commission's challenge of the Illumina merger with Grail, its much-needed boost to the Biden administration's antitrust agenda, and some silver linings the decision offers to merging parties.

  • A Potential Proactive Tool For Public-Private Joint Ventures

    Author Photo

    In the current environment of heightened antitrust enforcement, the National Cooperative Research and Production Act seems tailor-made for the collaborative work among competitors encouraged by the Biden administration's infrastructure and green energy funding legislation, say Jeetander Dulani and Susan Ebner at Stinson.

  • Financing Healthcare Deals In Uncertain Markets This Year

    Author Photo

    As challenges to closing and financing new deals prevail into 2024, lenders in new healthcare transactions are talking about alternative approaches for sponsors to consider, such as private credit alternatives and utilization of junior capital, say attorneys at McDermott.

  • A Primer On New Calif. Health Transaction Reporting Rules

    Author Photo

    New California regulations regarding the reporting of certain transactions involving healthcare entities, which took effect on Jan. 1, address some industry feedback about overly broad requirements but still leave several areas of concern, says Andrew Demetriou at Husch Blackwell.

  • In The CFPB Playbook: Rulemaking Rush Before Election Year

    Author Photo

    In this quarterly Consumer Financial Protection Bureau activity recap by former bureau personnel, attorneys at McGuireWoods explain the regulator's recent push to finalize new rules about data aggregators, digital payment apps and more before the election-year Congressional Review Act window opens.

  • What The Law Firm Of The Future Will Look Like

    Author Photo

    As the legal landscape shifts, it’s become increasingly clear that the BigLaw business model must adapt in four key ways to remain viable, from fostering workplace flexibility to embracing technology, say Kevin Henderson and Eric Pacifici at SMB Law Group.

  • 4 PR Pointers When Your Case Is In The News

    Author Photo

    Media coverage of new lawsuits exploded last year, demonstrating why defense attorneys should devise a public relations plan that complements their legal strategy, incorporating several objectives to balance ethical obligations and advocacy, say Nathan Burchfiel at Pinkston and Ryan June at Castañeda + Heidelman.

  • What Insurers Gain When Litigating Coverage Denials

    Author Photo

    Lately, insurance companies have denied coverage for lawsuits alleging liability relating to the ordinary operations of highly regulated businesses, such as those in the pharmaceutical and energy sectors — demonstrating time and again how litigation can be a vehicle for carriers to mitigate their own costs, say attorneys at Reed Smith.

  • Law Firm Strategies For Successfully Navigating 2024 Trends

    Author Photo

    Though law firms face the dual challenge of external and internal pressures as they enter 2024, firms willing to pivot will be able to stand out by adapting to stakeholder needs and reimagining their infrastructure, says Shireen Hilal at Maior Consultants.

  • AI In Health Law: The Top Guest Articles Of 2023

    Author Photo

    As the use of artificial intelligence accelerated this year, Expert Analysis writers examined AI's significant impact on the healthcare sector, ranging from key compliance considerations for companies utilizing AI tools to regulators' efforts to keep up with rapidly evolving technologies.

  • The Most-Read Legal Industry Law360 Guest Articles Of 2023

    Author Photo

    A range of legal industry topics drew readers' attention in Law360's Expert Analysis section this year, from associate retention strategies to ethical billing practices.

  • How SEC And NY Cyber Reporting Rules Affect Key Industries

    Author Photo

    The new U.S. Securities and Exchange Commission and New York State Department of Financial Services cybersecurity disclosure requirements, and their competing obligations, reveal the increasing complexity for organizations evaluating and reacting to cybersecurity incidents — particularly those in the healthcare and financial services industries, say attorneys at Manatt.